2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - Hall B
This partial session is a mix of important abstracts of molecular observations in MPNs and Histiocytic Disorders. Suggested title (After discussion with other Lead reviewer Florian Heidel:  <blockquote type="cite" style="margin: 0px 10px !important; caret-color: #212121; color: #212121; font-family: Aptos; font-size: 16px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-line: none; text-decoration-thickness: auto; text-decoration-style: solid;"> <div> <div> <div style="direction: ltr; font-family: Aptos, Arial, Helvetica, sans-serif; font-size: 12pt;">Molecular Insights and New Approaches in MPNs</div> </div> </div> </blockquote>
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Biological Therapies, Non-Biological Therapies, Biological Processes, CHIP, Hematopoiesis, Metabolism, Diseases, Genetic Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

927 Efficacy of targeted therapy and chemotherapy in adult histiocytic neoplasms in the frontline setting: An international multicenter cohort study

Carla Isabel Borre, MD, MPH, Long Chang, MD2, Grant Spears3, Aishwarya Pradeep, MD4, Jacquelyn Elise Fitzgerald Fitzgerald, BS5, Brinda Shukla6, Xi Yang, MD7, David Pottinger8, Fnu Amisha9, Pujan Patel10, Aldo A Acosta Medina, MD11, Dongni Yi, MD12, Pranay Juneja13, Nitya Malhotra14, William Oliver Tobin, MD15, Jason Young, MD16, Corrie Bach17, Matthew J Koster, MD18, Nora Bennani, MD19, Mithun Shah, MD, PhD20, Robert Vassallo21, Julio C. Sartori Valinotti22, Jay Ryu23, Lucinda Gruber24, Surendra Dasari, Associate Professor25, Aishwarya Ravindran, MBBS26, Karen Rech27, Rohan Halder, MD, DM28, Muhamad Alhaj Moustafa, MD, MS29, Talal Hilal, MD30, Thomas Witzig, MD31, Ronald Go, MD32, Asra Ahmed, MD33, Aki Sato34, Samuel Benjamin Reynolds, MD35, Gaurav Goyal, MD36, Xinxin Cao, MD37, Jithma Abeykoon, MD38
1 Mayo Clinic, Rochester, Minnesota, United States
2 Peking Union Medical College Hospital, Pekin, China
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 University of Alabama at Birmingham, Birmingham, Alabama, United States
6 University of Alabama at Birmingham, Birmingham, Alabama, United States
7 University of Michigan, Ann Arbor, Michigan, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 University of South Florida, Tampa, Florida, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States
26 Mayo Clinic, Rochester, Minnesota, United States
27 Mayo Clinic, Rochester, Minnesota, United States
28 Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India
29 Mayo Clinic, Jacksonville, Florida, United States
30 Mayo Clinic, Phoenix, Arizona, United States
31 Mayo Clinic, Rochester, Minnesota, United States
32 Mayo Clinic, Rochester, Minnesota, United States
33 University of Michigan, Ann Arbor, Michigan, United States
34 The University of Tokyo, Tokyo, Japan
35 Moffitt Cancer Center, Tampa, Florida, United States
36 University of Alabama at Birmingham, Birmingham, Alabama, United States
37 National Cancer Center, Beijing, China
38 Mayo Clinic, Rochester, Minnesota, United States

Background: MAPK-directed targeted therapy (TT) has transformed adult histiocytic neoplasms (HN) but requires indefinite treatment, carries cumulative toxicity, and is limited by cost/access. Fixed-duration chemotherapy (CT) remains a common frontline strategy, especially in adult Langerhans cell histiocytosis (LCH). These approaches have not been evaluated side by side in adult HN.

Methods: International retrospective cohort across 9 centers (Mayo Clinic Rochester/Phoenix/Jacksonville, University of Michigan, University of Alabama at Birmingham, Moffitt Cancer Center, Peking Union Medical College Hospital, University of Tokyo, Rajiv Gandhi Cancer Institute). Adults (≥18 years) with biopsy-confirmed Erdheim-Chester disease (ECD), LCH, or Rosai-Dorfman disease (RDD) treated with frontline TT or CT (1983-2025) were included. Primary endpoint was progression-free survival (PFS); secondary endpoints were overall response rate (ORR), overall survival (OS), time-to-next-treatment (TTNT), and toxicity. Patients receiving radiation, surgery, or steroids within 6 months remained classified by systemic therapy. Response was assessed by PET-CT using Deauville criteria; CT or MRI were used when PET-CT was unavailable. In Cox models, risk-organ involvement was defined as spleen, liver, CNS, or bone marrow disease; multi-organ disease as ≥2 involved organs.

Results: Among 499 patients (ECD n=132, LCH n=317, RDD n=50), 164 (32.9%) received TT and 335 (67.1%) CT. TT use was 81.8% in ECD, 60.0% in RDD, and 8.2% in LCH. TT included MEK inhibitors (n=83, 50.6%), BRAF inhibitors (n=74, 45.1%), and combined BRAF/MEK inhibition (n=7, 4.3%); CT included nucleoside analog-based (n=260, 77.6%), methotrexate-based (n=39, 11.6%), vinblastine-based (n=26, 7.8%), and other regimens (n=10, 3.0%). Median follow-up was 4.1 years (95% CI 3.6–4.8) in ECD, 5.1 years (4.6–5.5) in LCH, and 2.4 years (2.0–4.6) in RDD, and was shorter with TT than CT in all diseases. MAPK alterations were detected in 77.4% of tested ECD, 58.0% of LCH, and 50.0% of RDD patients. BRAF-V600E was enriched among TT-treated ECD (56.3% vs 33.3%; p=.017) and LCH (82.6% vs 38.3%; p<.001).

In ECD, ORR was higher with TT than CT (90.7% vs 60.9%; p<.001), with stable disease more frequent with CT (30.4% vs 4.1%). ORR was similar in LCH (81.8% vs 90.8%; p=.17) and RDD (69.2% vs 78.9%; p=.47). Among patients with CNS involvement, ECD ORR was 92.7% with TT versus 33.3% with CT (p=.003), whereas both approaches achieved high ORRs in CNS LCH (100% [7/7] vs 81.6% [31/38]; p=.57). Among 227 response-evaluable MAPK-altered patients, ORR was similar with TT and CT (88.1% vs 86.4%; p=.84); MAPK-altered LCH responded frequently to CT (90.4%). Findings were unchanged in the PET era (2015+).

Adjusted for age, sex, risk-organ, and multi-organ involvement, PFS, OS, and TTNT did not differ between TT and CT in ECD (PFS HR 0.82, 95%CI 0.36-1.86; OS HR 1.28, 0.51-3.21; TTNT HR 1.03, 0.51-2.09) or LCH (PFS HR 2.03, 0.81-5.08; OS HR 3.43, 0.44-26.43; TTNT HR 1.18, 0.60-2.30); HRs are for CT with TT as reference. RDD multivariable models were not estimable. Four-year PFS/OS were 65.0%/84.2% with TT and 68.6%/87.3% with CT in ECD; 75.9%/96.2% and 54.6%/93.9% in LCH. Two-year PFS/OS in RDD were 75.1%/100% and 58.2%/89.2%. At 4 years, 57.2% (TT) and 57.7% (CT) of ECD patients and 60.1% (TT) and 53.6% (CT) of LCH patients had not started a next line of therapy, as had 67.9% (TT) and 45.5% (CT) of RDD patients at 2 years. Sensitivity analyses in BRAF-V600E-mutated and MAPK-altered patients were unchanged.

Overall adverse-event rates were similar (76.2% TT vs 74.0% CT; p=.60), but grade ≥3 events were less frequent with TT (8.5% vs 32.5%; p<.001). Dose modification (41.5% vs 7.8%) and discontinuation for toxicity (23.8% vs 7.2%) were more common with TT (both p<.001). TT toxicity was mainly dermatologic, gastrointestinal, and cardiovascular; CT mainly hematologic.

Conclusions: In the largest frontline adult HN cohort reported, TT improved response in ECD but not adjusted PFS, OS, or TTNT in any subtype. CT achieved high response rates in adult LCH, including CNS disease. Limitations include the retrospective design, residual confounding, heterogeneous CT regimens, non-standardized response/toxicity assessment, shorter TT follow-up, and small RDD and TT-treated LCH cohorts. These findings favor individualized frontline treatment based on subtype, molecular profile, toxicity, access, and patient preference.

Carla Isabel Borre, MD, MPH: No relevant conflicts of interest to declare.